Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia
- 995 Downloads
Purpose of Review
We reviewed recent diagnostic and therapeutic progress in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). We summarized recent genetic data that may guide future efforts towards implementing risk-adapted therapy based on mutational profile and improving disease control and survival of affected patients.
Recent genetic data in CNL and aCML prompted modifications to the World Health Organization (WHO) diagnostic criteria, which have improved our understanding of how CNL and aCML are different diseases despite sharing common findings of peripheral granulocytosis and marrow myeloid hyperplasia. The overlap of recurrently mutated genes between aCML and CMML support considering CSF3R-T618I mutated cases as a distinct entity, either as CNL or CNL with dysplasia. Ongoing preclinical and clinical studies will help to further inform the therapeutic approach to these diseases.
Our understanding of CNL and aCML has greatly advanced over the last few years. This will improve clarity for the diagnosis of these diseases, provide a strategy for risk stratification, and guide risk-adapted therapy.
KeywordsChronic neutrophilic leukemia Atypical chronic myelogenous leukemia Colony-stimulating factor 3 receptor (CSF3R) JAK-STAT signaling Myelodysplasia/myeloproliferative neoplasm (MDS/MPN)
K.T.D. is supported by the Knight Cancer Institute. J.W.T. is supported by the Leukemia & Lymphoma Society, the V Foundation for Cancer Research, Gabrielle’s Angel Foundation for Cancer Research, and the National Cancer Institute (5R00CA151457-04; 1R01CA183947-01). J.G. is supported by the Charles and Ann Johnson Foundation.
Compliance with Ethical Standards
Conflict of Interest
All authors on this manuscript are investigators of the NCT02092324 clinical trial evaluating the safety and efficacy of ruxolitinib (Incyte Corporation) in patients with aCML and CNL. Incyte is providing financial support of this trial. The authors do not perceive any conflict of interest in their presentation of data and preparation of this manuscript. K.T.D. and J.G. additionally serve on advisory board activities sponsored by Incyte and receive honoraria in support of their participation.
Jeffrey W. Tyner reports grants from Agios, Aptose, Array, AstraZeneca, Constellation, Genentech, Incyte, Janssen, Seattle Genetics, Syros, Takeda, and other from Leap Oncology outside the submitted work.
Kim-Hien T. Dao and Jason R. Gotlib reports grants and other from Incyte Corporation outside the submitted work.
Human and Animal Rights and Informed Consent
This article contains no studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 2.•• Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. Summary of expected changes to WHO CNL and aCML diagnostic criteria CrossRefPubMedGoogle Scholar
- 15.Stein BL, Tiu RV. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. Journal of Interferon & Cytokine Research: The Official Journal of the International Society for Interferon and Cytokine Research. 2013;33(4):145–53.CrossRefGoogle Scholar
- 25.•• Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–90. CSF3R -T618I first reported as a common oncogenic driver in CNL and some aCML CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Lasho TL, Mims A, Elliott MA, Finke C, Pardanani A, Tefferi A. Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia. 2014;28(6):1363–5.CrossRefPubMedGoogle Scholar
- 29.Nooruddin Z, Miltgen N, Wei Q, Schowinsky J, Pan Z, Tobin J, et al. Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica. 2017;102(5):e207–e9.CrossRefPubMedPubMedCentralGoogle Scholar
- 31.Gunawan AS, McLornan DP, Wilkins B, Waghorn K, Hoade Y, Cross NCP, et al. Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent CSF3R mutations in chronic neutrophilic leukemia. Haematologica. 2017;102(6):e238–e40.CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, et al. Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms. Eur J Haematol. 2014;92(3):189–94.CrossRefPubMedGoogle Scholar
- 35.•• Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M, et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant. 2004;34(12):1047–50. Only case series documenting outcomes after allogeneic stem cell transplantation in aCML CrossRefPubMedGoogle Scholar
- 36.•• Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson RA, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–3. CSF3R -T618I reported as a highly specific oncogenic driver in CNL CrossRefPubMedPubMedCentralGoogle Scholar
- 37.• Meggendorfer M, Haferlach T, Alpermann T, Jeromin S, Haferlach C, Kern W, et al. Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. Haematologica. 2014;99(12):e244–6. Compares specific mutations in CNL, aCML, and CMML CrossRefPubMedPubMedCentralGoogle Scholar
- 38.• Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, et al. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood. 2014;123(17):2645–51. Describes distinct features between aCML and MDS/MPN unclassifiable in a large data set CrossRefPubMedPubMedCentralGoogle Scholar
- 48.• Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;27(9):1852–60. Survey of SETBP1 mutations among aCML and MDS/MPN subtypes CrossRefPubMedGoogle Scholar
- 50.Patnaik MM, Barraco D, Lasho TL, Finke CM, Reichard K, Hoversten KP, et al. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. Am J Hematol. 2017;92(6):542-48. https://doi.org/10.1002/ajh.24722.
- 55.•• Fleischman AG, Maxson JE, Luty SB, Agarwal A, Royer LR, Abel ML, et al. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood. 2013;122(22):3628–31. Animal model confirming CSF3R -T618I mutation is oncogenic CrossRefPubMedPubMedCentralGoogle Scholar
- 56.•• Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, et al. The Colony-stimulating factor 3 receptor T640N mutation is oncogenic, sensitive to JAK inhibition, and mimics T618I. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2016;22(3):757–64. Animal model confirming CSF3R -T640N mutation is oncogenic CrossRefGoogle Scholar
- 57.Maxson JE, Luty SB, MacManiman JD, Abel ML, Druker BJ, Tyner JW. Ligand independence of the T618I mutation in the colony-stimulating factor 3 receptor (CSF3R) protein results from loss of O-linked glycosylation and increased receptor dimerization. J Biol Chem. 2014;289(9):5820–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 59.Zhang H, Means S, Schultz AR, Watanabe-Smith K, Medeiros BC, Bottomly D, et al. Unpaired extracellular cysteine mutations of CSF3R mediate gain or loss of function. Cancer Res. 2017;77(16):4258-67. https://doi.org/10.1158/0008-5472.CAN-17-1052.
- 60.Dong F, Qiu Y, Yi T, Touw IP, Larner AC. The carboxyl terminus of the granulocyte colony-stimulating factor receptor, truncated in patients with severe congenital neutropenia/acute myeloid leukemia, is required for SH2-containing phosphatase-1 suppression of Stat activation. Journal of Immunology (Baltimore, Md: 1950). 2001;167(11):6447–52.CrossRefGoogle Scholar
- 63.•• Rohrabaugh S, Kesarwani M, Kincaid Z, Huber E, Leddonne J, Siddiqui Z, et al. Enhanced MAPK signaling is essential for CSF3R-induced leukemia. Leukemia. 2017;31(8):1770-78. https://doi.org/10.1038/leu.2016.376.. MAPK signaling is involved in the pathogenesis of membrane-proximal CSF3R mutations.
- 64.• Shou LH, Cao D, Dong XH, Fang Q, Wu Y, Zhang Y, et al. Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: a meta-analysis. PLoS One. 2017;12(2):e0171608. Meta-analysis of SETBP1 mutations and impact on prognosis CrossRefPubMedPubMedCentralGoogle Scholar